MORAb 202

Drug Profile

MORAb 202

Alternative Names: Eribulin/farletuzumab antibody drug conjugate - Morphotek; Farletuzumab/eribulin ADC; MORAb-202

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Morphotek
  • Class Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action Apoptosis stimulants; Cadherin modulators; Folate receptor 1 antagonists; Receptor protein-tyrosine kinase modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 13 Nov 2017 Morphotek announces intention to submit IND to US FDA for Solid tumours in November 2017
  • 26 Oct 2017 Pharmacodynamics data from a preclinical study in Breast cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
  • 19 Sep 2017 Morphotek plans a clinical trial in Cancer in second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top